Proprotein Convertase Subtilisin Kexin 9 Inhibitors

Angela Pirillo, Alberico Luigi Catapano

Research output: Contribution to journalReview articlepeer-review


High levels of low-density lipoprotein cholesterol (LDL-C) are directly associated with an increased risk of cardiovascular disease. Reducing LDL-C levels reduces the incidence of cardiovascular events. Several lipid-lowering approaches are available to achieve the LDL-C levels recommended by current guidelines, statins being the first-line therapy. However, many patients cannot achieve the recommended LDL-C levels with current therapies. The discovery of the role of proprotein convertase subtilisin kexin 9 (PCSK9) in the regulation of plasma LDL-C levels suggested it as a potential pharmacologic target and led to the development of PCSK9 inhibitors for the management of LDL-C levels.

Original languageEnglish
Pages (from-to)241-256
Number of pages16
JournalCardiology Clinics
Issue number2
Publication statusPublished - May 1 2018


  • Alirocumab
  • Cardiovascular disease
  • Evolocumab
  • Hypercholesterolemia
  • LDL-C
  • Monoclonal antibodies
  • PCSK9
  • Proprotein convertase subtilisin kexin 9

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Proprotein Convertase Subtilisin Kexin 9 Inhibitors'. Together they form a unique fingerprint.

Cite this